ArticleCritical care science2025
Dynamics of anterior pituitary function in the acute phase of traumatic brain injury: a prospective cohort.
Article in Critical care science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTraumatic brain injury leads to disruption of the hypothalamic-pituitary axis. The aim of this study was to evaluate anterior pituitary gland function in the acute phase following traumatic brain injury and its relationship with patient outcomes.
methodsThis was a prospective cohort of traumatic brain injury patients admitted to the intensive care unit. The levels of adrenocorticotropic hormone, growth hormone, and thyroid-stimulating hormone on Days 0, 3 and 7 after the injury were measured. The Glasgow Outcome Scale-Extended (GOSE) was used for 6-month outcomes.
resultsA total of 88 traumatic brain injury patients (79% male, 41 ± 19 years old) who were admitted to the intensive care unit were studied. The frequencies of hormone levels below the range were as follows: adrenocorticotropic hormone, 81% on Day 0, 75% on Day 3, and 68% on Day 7; growth hormone, 76% on Day 0, 65% on Day 3, and 61% on Day 7; and thyroid-stimulating hormone, 42% on Day 0, 41% on Day 3, and 14% on Day 7. Traumatic brain injury severity was associated with Day 0 adrenocorticotropic hormone (p = 0.03) and Day 7 growth hormone (p = 0.03) levels and inversely associated with Day 3 thyroid-stimulating hormone (p = 0.03) levels. Glial fibrillary astrocytic protein was directly associated with Day 3 adrenocorticotropic hormone (OR 1.02, 95%CI 1.01 - 1.03; p < 0.001) and inversely associated with Day 7 thyroid-stimulating hormone (OR 1.02, 95%CI: 1.02 - 1.03; p = 0.04) levels. There was no significant association between hormone levels and mortality or the 6-month Glasgow Outcome Scale-Extended score.
conclusionAnterior pituitary hormone disturbances are common following a traumatic brain injury, and the degree of dysfunction is related to the injury severity. No associations were found with mortality or disability. Further investigations are warranted to standardize the measurement of pituitary function after traumatic brain injury and clarify its prognostic/therapeutic role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.